Therefore, We should fully evaluate the risk of recurrence of breast cancer patients, such as hormone receptor status, HER2 expression, lymph node metastasis, etc., and then choose the appropriate treatment plan to bring the greatest benefit to patients. The gene discussed is ERBB2; the disease is metastatic malignant neoplasm in the lymph nodes.